Diagnosing Dx

This week on Diagnosing Dx, I’m joined by Rachel Jones,former Chief Commercial Officer at BioFire and now at VedaBio. Rachel shares her remarkable journey from bench scientist to helping rebrand Idaho Technology into BioFire, scaling its commercial team from just 12 people into a billion-dollar diagnostics powerhouse, and ultimately shaping one of the most iconic success stories in infectious dise...

This week on Diagnosing Dx, I’m joined by Bradley Murray, CEO and co-founder of Delve Bio. Bradley shares his journey from academic research, success as a biotech startup, investment into life sciences and onto entrepreneurship, andhow those experiences shaped his approach to building diagnostics that put patients first.   We dive into why execution, not just vision is critical for survival in tod...

This week on Diagnosing Dx, I’m joined by Tara Maddala,statistician, diagnostics veteran, and founder of Pandora Bio and Tiger Team Bio, whose career also spans Genomic Health and Grail.   We explore how the truth-seeking culture at Genomic Healthshaped her approach to building and advising early-stage companies, why mental health diagnostics is still decades behind, and how AI is often misreprese...

This week on Diagnosing Dx, I’m joined by Mark Oldroyd, a commercialisation strategist with over 30 years in healthcare, including leadership roles at Foundation Medicine, Tempus, and C2i Genomics.   Mark has guided diagnostics and omics companies across the US, Europe, and Asia, helping them find the right path from breakthrough science to a sustainable business.   🔥What You’ll Learn: • Why movi...

This week on Diagnosing Dx, I’m joined by James Kelley, Chief Medical Officer at Pictor Labs and a respected leader in lab medicine and diagnostics. We explore how AI is reshaping pathology, what makes virtual staining such a transformative innovation, and why data ownership and transparency are becoming urgent conversations for clinicians. From regulatory frameworks to AI education in healthcare,...

This week on Diagnosing Dx, I’m joined by Vincent Funari, a genomics leader whose career spans from the Human Genome Project to pioneering liquid biopsy assays and driving innovation at NeoGenomics during its major growth years.   We dive into how Vincent scaled R&D through M&A, led testing innovation during the COVID-19 crisis, and earned praise from the FDA for breakthrough assay develop...

On this week’s episode of Diagnosing Dx, I’m joined by Mort Minaee, a seasoned regulatory strategist with over 35 years of experience at companies like Roche, Abbott, and Guardant Health. We unpack the FDA’s recent ruling, and reversal on LDTs (Laboratory Developed Tests) and what this moment of uncertainty means for diagnostics startups. Mort shares how to build a credible regulatory strategy tha...

This week on Diagnosing Dx, I’m joined by Janine McMurdie, Chief Commercial Officer at Pictor, a company unlocking the next wave of innovation in diagnostics through proteomics. With a career spanning industry giants like Amgen and IonTorrent, Janine shares what it takes to lead in a fast-evolving space - where scalability, speed, and strategy matter more than ever. We dive into how Pictor’s flexi...

This week on Diagnosing Dx, I’m joined by Dr. Sam Agus, a neurologist and diagnostics innovator with over 20 years of experience in clinical trials, biomarker development, and early-stage ventures.   In this candid conversation, Sam shares the hard truths about why diagnostics companies struggle for funding, why prognostics are quietly becoming the next frontier, and how early partnerships - espec...

This week on Diagnosing Dx, we’re joined by Kim Langone, SVP of R&D at Fellow Health, and former 10th employee at Genomic Health, where for 19 years, she played a pivotal role in developing Oncotype DX, a landmark diagnostic test for breast cancer.   With 24 years of experience in molecular diagnostics, Kimshares what it takes to build breakthrough science in a startup, scale it, and navigate...

This week on Diagnosing Dx, we’re joined by Heinz Steneberg, President and CEO of MDSS, for a deep dive into the role of Regulatory Strategy in Diagnostics and MedTech startups. From early-stage planning to FDA engagement, we cover the decisions that make or break go-to-market timelines - and how emerging models are shaping the regulatory future. 🔥 What You’ll Learn: • How to use FDA pre-submissi...